

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Article

**Clinical evolution of New Delhi Metallo- β -lactamase (NDM) optimizes
resistance under Zn(II) deprivation**

Guillermo Bahr^{1,2}, Luisina Vitor-Horen¹, Christopher R. Bethel³, Robert A.
Bonomo^{3,4,5},
Lisandro J. González^{1,2#}, Alejandro J. Vila^{1,2,5#}

¹ Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR),
Rosario, Argentina.

² Área Biofísica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad
Nacional de Rosario, Rosario, Argentina.

³ Research Services, Louis Stokes Cleveland Department of Veterans Affairs
Medical Center, Cleveland, OH 44106, United States;

⁴ Departments of Medicine, Pharmacology, Molecular Biology and Microbiology,
Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University
School of Medicine, Cleveland, OH 44106, United States;

⁵ CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology,
Cleveland, OH 44106, United States.

Running Title: Molecular Features in the Evolution of NDM lactamase

To whom correspondence should be addressed:

20

lgonzalez@ibr-conicet.gov.ar, vila@ibr-conicet.gov.ar

21

22 **ABSTRACT**

23 Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly spreading and
24 taking a staggering toll on all healthcare systems, largely due to the dissemination
25 of genes coding for potent carbapenemases. An important family of
26 carbapenemases are the Zn(II)-dependent β -lactamases, known as Metallo- β -
27 lactamases (MBLs). Among them, the New-Delhi Metallo- β -lactamase (NDM) has
28 experienced the fastest and widest geographical spread. While other clinically
29 important MBLs are soluble periplasmic enzymes, NDM β -lactamases are
30 lipoproteins anchored to the outer membrane in Gram-negative bacteria. This
31 unique cellular localization endows NDM with an enhanced stability upon the Zn(II)
32 starvation elicited by the immune system response in the sites of infection. Since
33 the first report of NDM-1 β -lactamase, new allelic variants (16 in total) have been
34 identified in clinical isolates, differing by a limited number of substitutions. Here we
35 show that these variants have evolved by accumulating mutations that enhance
36 their stability or the Zn(II) binding affinity *in vivo*, overriding the most common
37 evolutionary pressure acting on catalytic efficiency. We identified the ubiquitous
38 mutation M154L as responsible of improving the Zn(II) binding capabilities of the
39 NDM variants. These results also reveal that Zn(II) deprivation imposes a strict
40 constraint in the evolution of this MBL, overriding the most common pressures
41 acting on catalytic performance, and shed light on possible inhibitory strategies.

42

43

44 INTRODUCTION

45 Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly spreading and
46 taking a staggering toll on all healthcare systems (1, 2), largely due to the
47 dissemination of genes coding for potent carbapenemases (3). Metallo- β -
48 lactamases (MBLs) are Zn(II)-dependent enzymes that represent one of the largest
49 group of carbapenemases. MBLs are able to hydrolyze not only carbapenems, but
50 also penicillins and cephalosporins with comparable performances (4, 5). They
51 include the families of plasmid-encoded IMP, VIM and NDM enzymes, which have
52 disseminated worldwide among opportunistic and pathogenic bacteria. These
53 enzymes are not affected by the action of serine- β -lactamase inhibitors, including
54 the newly developed avibactam, and there are not specific inhibitors for MBLs
55 available in the clinic.

56 The New-Delhi Metallo- β -lactamase (NDM) has experienced the fastest and
57 widest geographical (6, 7) spread among MBLs in recent years. The clinical
58 success of NDM has been attributed to the fact that it is a lipoprotein anchored to the
59 outer membrane in Gram-negative bacteria (Fig. 1B) (8-10). This feature is
60 exclusive to this enzyme in contrast to all other MBLs, which are soluble
61 periplasmic proteins (5). We have recently suggested (9) that this cellular
62 localization can boost the fitness of NDM-1 under physiological conditions. At the
63 sites of infection, pathogens must face the “nutritional immunity” response by the
64 host immune system, which involves the release of large amounts of the metal-
65 chelating protein calprotectin. As a consequence, Zn(II) levels in the bacterial
66 periplasm decrease, leading to accumulation of apo (non-metallated) MBLs, that

67 are susceptible to proteolytic degradation (9). Membrane anchoring prevents
68 degradation of apo-NDM-1 upon this Zn(II) starvation process (9).

69 Since the first report of NDM-1 (11), new allelic variants (16 in total) have
70 been identified in clinical isolates, differing by a limited number of substitutions
71 (12). The 16 NDM variants are characterized by substitutions at a relatively small
72 number of positions, all occurring outside the active site (Fig. 1). Residue M154 is
73 the most frequently substituted, with M154L being the most common change
74 (found in the single mutant NDM-4 and in six double mutants: NDM-5, NDM-7,
75 NDM-8, NDM-12, NDM-13 and NDM-15), and one occurrence of M154V (in NDM-
76 11). Residue D130 is replaced in 3 alleles, with substitutions D130G (NDM-8 and
77 NDM-14) and D130N (NDM-7). Substitutions D95N and A233V are present in two
78 alleles each, both as single variants (NDM-3 and NDM-6) and in combination with
79 M154L (NDM-13 and NDM-15) (Fig. 1A). However, comparative studies of MBL
80 proteins NDM 1-8 have not revealed significant differences in their resistance
81 profiles nor in the *in vitro* activities of the purified, soluble forms of these enzymes
82 (with truncated lipidation sites) (13). These observations cannot account for the
83 selection of these alleles in clinical environments.

84 We contend that the expression of NDM variants should be evaluated in
85 conditions as close as possible to the physiological ones: (1) in the membrane-
86 bound form, and (2) under environmental conditions of Zn(II) deprivation (9, 14,
87 15). Here we examine the resistance profiles of the different NDM variants under
88 these conditions, identify the molecular features responsible for the observed
89 phenotypes, and demonstrate that NDM variants are evolving by enhancing their

90 Zn(II) binding capability *in vivo*. These results also reveal that Zn(II) deprivation has
91 imposed a strict constraint in the evolution of this MBL, overriding the most
92 common pressures acting on catalytic performance, and shed light on possible
93 inhibitory strategies.

94 RESULTS

95 To compare the performance of NDM variants within a common
96 physiological background, we expressed the *bla*_{NDM} genes coding for all 16 alleles
97 in an isogenic *E. coli* strain with their native signal peptide, targeting the variants to
98 the outer membrane with expression levels similar to those observed in clinical
99 strains (9, 16). To ensure homogeneous immunodetection and quantitation, all
100 variants were expressed fused to a common C-terminal Strep-tag, which does not
101 affect resistance (9). Expression of *bla*_{NDM} alleles resulted in similar protein levels,
102 except for NDM-10 (harboring 5 substitutions), displaying a 5-fold reduction with
103 respect to NDM-1 (Fig. S1). In the case of NDM-2, carrying mutation P28A, 20% of
104 the total protein was found as a soluble, non-lipidated periplasmic lactamase,
105 indicating that mutations proximal to the lipidation site (C26) can affect membrane
106 anchoring.

107 In these constructs, minimum inhibitory concentrations (MICs) of piperacillin
108 (PIP), cefepime (FEP), cefotaxime (CTX) and imipenem (IPM) for most variants did
109 not reveal major differences among *bla*_{NDM} alleles (Table S1), except for *bla*_{NDM-10}.
110 This quintuple mutant displayed significantly lower MIC values, that we attribute to
111 the lower protein levels of this variant. Overall, these resistance profiles do not

112 differ from those reported for alleles $bla_{\text{NDM 1-8}}$ (13). However, the experimental
113 conditions employed to study the resistance profile may not always reflect the
114 actual environment that is acting in selection (17). For instance, the standard
115 conditions used for MIC determinations involve media with high Zn(II) content that
116 do not represent the environment at infection sites, where potent metal-
117 sequestering proteins such as calprotectin (CP) are released by the host immune
118 system (10, 18-21). We therefore evaluated the impact of Zn(II) deprivation in MIC
119 values by adding the chelating agent dipicolinic acid (DPA) to the medium. It has
120 already been shown that DPA can mimic the effect elicited by the action of CP,
121 without being lethal for bacteria (9).

122 These experiments (summarized in Fig. 2) revealed that: (1) MIC values
123 were affected by addition of DPA; and (2) the response was strongly allele-
124 dependent. In general, the impact of Zn(II) deprivation on MIC values was
125 noticeable at DPA levels higher than 350 μM (Fig. 2 and Table S2). Most NDM
126 variants granted higher MIC values than NDM-1 at DPA levels beyond this value.
127 NDM-10 was an exception, since resistance levels for this variant were drastically
128 abolished at low concentrations of DPA. These results clearly show that the amino
129 acid substitutions have a defined and distinct impact in the ability to endure Zn(II)
130 starvation.

131 NDM variants can be classified into four groups according to the
132 dependence of resistance on DPA concentration. *Tier 1* alleles are those
133 displaying the highest tolerance to Zn(II) scarcity: NDM-15 (M154L A233V), NDM-
134 13 (D95N M154L), NDM-12 (M154L G222D), NDM-8 (D130G, M154L), NDM-7

135 (D130N M154L), and NDM-5 (V88L M154L). *Tier 2* alleles possess greater
136 tolerance to Zn(II) starvation than NDM-1, with MICs at least one 2-fold dilution
137 below the lowest of *Tier 1* variants. *Tier 2* includes NDM-14 (D130G), NDM-9
138 (E152K), NDM-6 (A233V), NDM-4 (M154L) and NDM-3 (D95N). *Tier 3* MBLs
139 behave similarly to NDM-1, and includes NDM-16 (R264H), NDM-11 (M154V),
140 NDM-2 (P28A) and NDM-1. Finally, *Tier 4* contains NDM-10, the only allele that
141 performs worse than NDM-1.

142 *Tier 1* consists of double mutants while *Tier 2* contains only single mutants,
143 indicating that variants with two mutations possess a higher ability to confer
144 resistance under low Zn(II) conditions. This observation suggests that tolerance to
145 Zn(II) starvation is selected as mutations accumulate during the evolution of NDM.
146 Furthermore, all *Tier 1* variants possess substitution M154L, which seems crucial
147 for adaptation to low Zn(II) availability. This enhancement can in principle be
148 attributed to the specific presence of a leucine residue in position 154, since NDM-
149 11 (M154V) displays a behavior similar to NDM-1 upon addition of DPA (Fig. 2).

150 We interrogated the role of residue 154 by performing site-saturation
151 mutagenesis on NDM-1 at this position. MIC values of cefotaxime were within one
152 dilution of NDM-1 for seven out of the nineteen mutants, revealing that position 154
153 is highly tolerant to substitutions (Table S3), in agreement with its location near the
154 protein surface (Fig. 1B). In the presence of DPA, however, only variant M154L
155 (NDM-4) provided higher levels of resistance than NDM-1 upon Zn(II) starvation,
156 while all others were more susceptible (Fig. S2). The selection of replacement
157 M154L in a position highly tolerant to mutations strongly suggests that Zn(II)

158 deprivation has exerted a significant evolutionary pressure in the natural selection
159 of NDM alleles.

160 We next aimed to characterize the molecular features giving rise to these
161 phenotypes. Zn(II) starvation elicits degradation of MBLs within the periplasmic
162 space, since the apo-enzymes (Zn(II)-free forms) are susceptible to proteolysis
163 while the metal-bound proteins are stable (9). We interrogated the *in vivo* stability
164 of NDM alleles upon Zn(II) depletion by monitoring the time evolution of the NDM
165 protein levels in *E. coli* cells after addition of DPA to the growth medium (Fig. S3).
166 Under these conditions, NDM-1 experienced >90% degradation within 60 minutes,
167 with a half-life of ca. 9 minutes. Degradation rates were highly variable among
168 NDM alleles, with half-lives spanning from 2 to 75 min (Fig. 3). Most variants
169 performed better or similar to NDM-1.

170 The NDM variants can be classified into four groups according to their
171 stability profiles: (1) proteins with an enhanced stability against degradation ($t_{1/2}$
172 between 75 and 53 min): NDM-15 (M154L A233V), NDM-6 (A233V) and NDM-9
173 (E152K); (2) proteins more stable than NDM-1 ($t_{1/2}$ between 20 and 17 min): NDM-
174 5 NDM-7 (D130N M154L), NDM-12 (M154L G222D) and NDM-13 (D95N M154L);
175 (3) proteins with a stability similar to NDM-1 ($t_{1/2}$ between 13 and 8 min): NDM-2
176 (P28A), NDM-3 (D130G), NDM-4 (M154L), NDM-11 (M154V) and NDM-16
177 (R264H); and (4) proteins with a markedly lower stability than NDM-1 ($t_{1/2} < 2$ min):
178 NDM-10. Analysis of these data reveals that most double variants exhibited a
179 greater stability than NDM-1, except NDM-8 (M154L D130G) which was
180 comparable to NDM-1. Among point mutations present in NDM alleles,

181 substitutions A233V and E152K were shown to be stabilizing, giving rise to the only
182 single variants displaying high stability: NDM-6 and NDM-9. The most stable NDM
183 mutants (groups 1 and 2) outperform even SPM-1, that was previously shown to be
184 the most stable MBL upon metal depletion under conditions similar to those
185 reported here (Figs. S4 and S5) (9, 15).

186 We next analyzed possible epistatic interactions between mutations. NDM-
187 15 (M154L A233V) shows a degradation profile similar to the single mutant NDM-6,
188 suggesting that its high stability is mostly due to mutation A233V, while the
189 stabilizing role of M154L is minor. A comparable stabilizing effect by mutation
190 M154L is observed when comparing NDM-4 with NDM-1. Variant NDM-13 (D95N
191 M154L) is more stable than the corresponding single mutants NDM-3 (D95N) and
192 NDM-4 (M154L), and both mutations may contribute to the increased stability.
193 NDM-8 (D130G M154L) is as stable as NDM-4, and thus D130G does not appear
194 to significantly contribute to stability. We conclude that the effects of the different
195 mutations on the stability are additive, with no evident epistatic interactions.

196 The degradation profiles upon Zn(II) starvation do not account for the
197 resistance provided by the alleles under these conditions: NDM-4 (M154L) and
198 NDM-11 (M154V) are degraded at a similar rate than NDM-1 (Fig. 3), but NDM-4
199 provides higher levels of resistance under Zn(II) deprivation (Fig. 2). Conversely,
200 NDM-6 (A233V) and NDM-15 (M154L A233V) show similar high stabilities, but
201 NDM-15 outperforms NDM-6 under Zn(II) starvation (Fig. 2). These observations,
202 together with the presence of mutation M154L in all *Tier 1* mutants, reveal that

203 M154L enhances resistance upon Zn(II) limiting conditions without imparting
204 protein stabilization.

205 Resistance at low Zn(II) levels can be optimized by two main mechanisms:
206 (1) improved stability of the apo-proteins or (2) optimization of the Zn(II) binding
207 affinity in the different variants, so that the accumulation of apo-proteins is
208 minimized. Thus, we evaluated the impact of positions 154 and 233 in the metal
209 binding affinity of variants NDM-1, NDM-4, NDM-6, NDM-11 and NDM-15, which
210 present mutations in these positions. To assess this property, we measured the β -
211 lactamase activity of these enzymes in spheroplasts containing the membrane-
212 bound forms challenged with DPA. Studies on spheroplasts allow direct
213 assessment of the enzymatic activity, being devoid of periplasmic proteases that
214 elicit protein degradation. In all cases, we observed a decrease in activity (Fig. 4)
215 with increasing concentrations of DPA. Immunoblotting experiments revealed
216 similar protein levels under these conditions (Fig. S6), showing that the decrease in
217 activity is not due to protein degradation, and therefore can be attributed to
218 accumulation of the inactive apo-proteins generated by the chelating agent. Thus,
219 the different behaviors of the alleles (Fig. 4) provide an estimate of the Zn(II)
220 affinity of each variant. NDM-4 (M154L) and NDM-15 (M154L A233V) displayed
221 the lowest susceptibility to inactivation by DPA, revealing that mutation M154L
222 indeed increases the metal binding ability, while the stabilizing mutation A233V
223 does not. Mutation M154V did not affect Zn(II) binding, in agreement with the
224 resistance profile observed for NDM-11 (Fig. 2). NDM-6 presented a similar
225 apparent affinity towards Zn(II) compared to NDM-1, confirming that mutation

226 A233V only impacts on the protein stability. This experiment allows us to propose
227 that the most frequent mutation (M154L) plays a crucial role in NDM fitness by
228 increasing the Zn(II) binding affinity.

229 Finally, we sought to directly compare the fitness of NDM alleles under
230 varying conditions of Zn(II) availability. To this end, we performed competition
231 experiments between *E. coli* cells expressing NDM-1, NDM-4, NDM-6 or NDM-15,
232 in presence of different concentrations of cefotaxime, and with or without addition
233 of metal chelators to the growth medium (Fig. 5). Both NDM-1 and single mutants
234 NDM-4 and NDM-6 displayed similar fitness in Zn(II)-rich conditions, i.e. growth
235 media not supplemented with DPA, and no allele seemed to be favored over the
236 other within the range of antibiotic concentrations tested (Fig. 5-A and B). In
237 contrast, NDM-1 and NDM-4 were selected over the double mutant NDM-15,
238 particularly at higher antibiotic concentrations (Fig. 5-C and D), in accordance with
239 their slightly higher MICs for CTX (128 vs 64-128 $\mu\text{g}/\text{mL}$). Competition experiments
240 carried out in presence of 250 μM DPA presented a radically different scenario.
241 Single mutants NDM-4 and NDM-6 were selected over NDM-1, and NDM-4 was
242 outcompeted by NDM-15. The double mutant was able to outperform NDM-1 more
243 effectively than single mutant variants, highlighting the gain in fitness due to
244 accumulation of beneficial mutations. Finally, we performed competition
245 experiments between NDM-1 and NDM-15 in the presence of calprotectin (Fig.
246 5D), obtaining results comparable to those with DPA. Thus, a similar differential
247 fitness is observed when trying to reproduce metal depletion by the host's
248 nutritional immunity response upon pathogenesis. The concentration of CP used

249 for the experiment (250 $\mu\text{g}/\text{mL}$) is within physiological range, since levels of up to
250 1000 $\mu\text{g}/\text{mL}$ have been reported in infection sites (20). These competition
251 experiments clearly reveal that alleles with better Zn(II) binding capability can
252 outcompete NDM-1 under these conditions, even at antibiotic concentrations well
253 below the MICs.

254

255 **DISCUSSION**

256 Assessment of the molecular features involved during the evolution of
257 resistance requires recreating as closely as possible the environmental conditions
258 that may have driven adaptation. For example, study of the evolution of the serine-
259 β -lactamase TEM at sub-lethal antibiotic concentrations, such as those present in
260 the environment, allowed an exhaustive exploration of the adaptive landscapes of
261 this protein, leading to increased diversity of this enzyme (17). Here we consider
262 that, during an infection, the host's immune system releases metal-chelating
263 proteins to inhibit the growth of bacteria, which in turn compete for these essential
264 nutrients by producing high affinity metal importers. In this context, MBLs should
265 possess optimized Zn(II) binding capabilities to effectively mediate β -lactam
266 resistance. In particular, clinically relevant MBLs require binding of two Zn(II) ions
267 in the periplasm to confer resistance (22). The requirements for Zn(II) binding are
268 stringent, since metal depletion leads to protein degradation, and loss of resistance
269 is more dramatic. Here we show that the resistance profiles of the known NDM
270 variants are similar when measured in Zn(II)-rich medium. Instead, significant

271 differences appear under Zn(II) deprivation conditions. We further show that most
272 variants are better suited to resist these conditions than NDM-1.

273 Our results suggest that the pathways along which NDM alleles are currently
274 evolving in clinical settings enhance the performance of these enzymes under low
275 Zn(II) availability. We identified two mechanisms behind this adaptation: a)
276 stabilization of otherwise unstable apo-enzymes, and b) enhancement of the Zn(II)
277 affinity to maintain high levels of the active species. Substitutions A233V and
278 E152K dramatically increase protein stability in the periplasm, while the highly
279 frequent mutation M154L enhances metal affinity. Both mechanisms can act
280 independently or combine without epistatic interactions to render enzymes with a
281 higher fitness under Zn(II) deprivation conditions (NDM-15). A small group of NDM
282 alleles (NDM-2, NDM-11 and NDM-16) did not show any advantages compared to
283 NDM-1 in our conditions. The mutations present in these variants may be neutral,
284 or be the result of a host specific adaptation as previously shown for SPM-1 (15),
285 that may not be evident in *E. coli* (e.g. NDM-2 has been only detected in
286 *Acinetobacter baumannii*) (12).

287 A recent work has revealed that evolution of the serine- β -lactamase TEM
288 has been shaped by optimization of the enzymatic efficiency (23), and not by
289 stabilization of the protein itself. Our results show that the adaptive landscape of
290 the metallo- β -lactamase NDM has been shaped by Zn(II) deprivation conditions,
291 leading to optimization of cofactor binding. In this regard, the identification of the
292 ubiquitous mutation M154L as responsible of increasing the Zn(II) binding affinity in
293 different alleles also provides a unique example of optimization of cofactor

294 assembly along evolution. This finding is in line with the reconstruction of the
295 evolutionary trajectory of an *in vitro* evolved MBL, that disclosed that the Zn(II)
296 binding affinity may be an essential feature in defining its fitness landscape (13).

297 Membrane localization is conserved among all NDM alleles, in contrast to
298 serine- β -lactamases which have in most cases foregone their membrane
299 anchoring during evolution from Penicillin Binding Proteins (PBPs) (24). This
300 contrast may be caused by the different fitness effects of membrane anchoring in
301 each class of enzyme, which ultimately impacts its evolutive fixation. It has been
302 shown that TEM is functional when anchored to the outer leaflet of the inner
303 membrane as its PBP predecessors, conferring the same resistance levels as the
304 native soluble protein without an apparent fitness advantage (24). Meanwhile, we
305 have previously shown that membrane anchoring of NDM-1 allows it to better
306 tolerate Zn(II) deprivation conditions (9), as soluble variants of the enzyme are less
307 stable and confer lower levels of resistance in low Zn(II) environments. The role of
308 membrane anchoring in stabilization would guarantee the conservation of this
309 characteristic. It should be noted that anchoring is but one mechanism accessible
310 to MBLs to improve stability under these conditions, as other MBLs such as SPM-1
311 or NDM variants carrying the A233V or E152K mutations also possess enhanced
312 stability against proteolytic degradation.

313 Despite the lack of clinically useful inhibitors, recent research has shown
314 that MBLs may also be challenged by compounds such as Aspergillomarasmine A
315 (AMA) (25), a Zn(II) chelator able to reverse resistance mediated by MBLs in
316 animal models. While NDM-1 was susceptible to inactivation by this compound,

317 SPM-1 proved to be refractory (25). Our results show that NDMs are evolving
318 beyond the AMA-resistant SPM-1 MBL, indicating that tolerance to low Zn(II)
319 availability will undoubtedly allow MBLs to circumvent this type of inhibition. This
320 stresses the need to develop specifically tailored inhibitors not dependent on metal
321 chelation to combat the growing threat posed by these enzymes.
322

323 **MATERIALS AND METHODS**

324 **Bacterial strains and reagents**

325 *Escherichia coli* DH5 α was used for expression of plasmid pMBLe, microbiological
326 and biochemical studies. Unless otherwise noted, all strains were grown
327 aerobically at 37 °C in lysogeny broth (LB) medium supplemented with gentamicin
328 20 μ g/mL when necessary. Chemical reagents were purchased from Sigma-
329 Aldrich, molecular biology enzymes from Promega, and primers from Invitrogen.

330

331 **Construction of NDM alleles**

332 *bla*_{NDM} variants genes were generated from pMBLe-*bla*_{NDM-1} (9), which contains the
333 full-length *bla*_{NDM-1} gene fused to a C-terminal Strep-Tag II sequence under control
334 of an IPTG-inducible pTac promoter. Variants were constructed by site-directed
335 mutagenesis as previously described (14) using the primers detailed in Table S4.

336 All constructs were verified by DNA sequencing (University of Maine, USA).

337

338 **Periplasm and spheroplasts preparations**

339 Extraction of periplasmic proteins was performed as previously described (9).

340 Briefly, 2–3 mL of *E. coli* pMBLe-*bla*_{NDM} cultures were pelleted and cells were
341 washed once with 20 mM Tris, 150 mM NaCl, pH 8.0. The washed cells were
342 resuspended in 20 mM Tris, 0.1 mM EDTA, 20% w/v sucrose, 1 mg/mL lysozyme
343 (from chicken egg white, Sigma-Aldrich, protein \geq 90%), 0.5 mM PMSF, pH 8
344 (resuspension volume was normalized according to the formula $V = 100 \mu\text{L} \times$
345 $\text{OD}_{600} \times V_c$, where V_c is the starting volume of culture sample), incubated with
346 gentle agitation at 4°C for 30 min, and finally pelleted, with the periplasmic extract

347 in the supernatant. The pellet consisting of spheroplasts was washed in 20 mM
348 Tris, 20% w/v sucrose, pH 8 and resuspended in the same volume of this buffer.
349

350 **MBL detection**

351 MBL protein levels were determined by SDS-PAGE followed by Western blot with
352 Strep-Tag® II monoclonal antibodies (at 1:1000 dilution from 200 µg/ml solution)
353 (Novagen) and immunoglobulin G-alkaline phosphatase conjugates (at 1:3000
354 dilution). Protein band intensities were quantified from PVDF membranes with
355 ImageJ software (26) and converted to relative protein amounts through a
356 calibration curve constructed under the same experimental conditions. In all cases,
357 Western blots with antibodies detecting GroEL were performed as loading controls.
358

359 **Minimum inhibitory concentration (MIC) determinations**

360 Cefotaxime, cefepime, piperacillin and imipenem MIC determinations were
361 performed in LB medium using the agar macrodilution method according to CLSI
362 guidelines (27). In order to measure the effect of Zn(II) availability on antibiotic
363 resistance, the growth medium was supplemented with varying concentrations of
364 the metal chelator dipicolinic acid (DPA) (Merck, >98%). In all cases, *bla*_{NDM}
365 expression was induced with 100 µM IPTG.

366 Relative MICs as plotted in Figures 2 and Figure S2 were calculated as $(MIC_{NDM} -$
367 $MIC_{control}) / (MIC_{NDM + 0 \mu M DPA} - MIC_{control + 0 \mu M DPA})$, where MIC_{NDM} and $MIC_{control}$ refer
368 to values measured for *E. coli* DH5α pMBLe-*bla*_{NDM} or pMBLe, respectively, under
369 each set of conditions, and $MIC_{NDM + 0 \mu M DPA}$ and $MIC_{control + 0 \mu M DPA}$, the
370 corresponding values in media without addition of DPA.

371

372 **Effect of external Zn(II) depletion in MBL protein levels**

373 *E. coli* pMBLe-*bla*_{NDM} cells were grown at 37°C up to an OD₆₀₀ of 0.4. MBL
374 expression was induced by the addition of 100 µM IPTG, and growth was
375 continued at 37°C for 2 h. At this time, cultures were divided in two equal parts.
376 One portion was treated with 500 µM DPA and the other kept as an untreated
377 control, and both cultures were grown at 37°C. Aliquots of DPA-treated and
378 untreated cultures were taken at different time intervals after DPA addition: 0, 10,
379 30 and 60 min, and processed for immunodetection. Protein values in DPA-treated
380 samples were reported relative to the corresponding values in untreated samples.

381

382 **Competition experiments**

383 Isogenic *E. coli* W3110(28) and *E. coli* W3110 Δ *lacZ* (29) strains were transformed
384 with pMBLe-*bla*_{NDM-15}, pMBLe-*bla*_{NDM-6}, pMBLe-*bla*_{NDM-4} and pMBLe-*bla*_{NDM-1}. Pairs
385 of strains expressing different NDM alleles in opposite Lac phenotype backgrounds
386 (e.g. *E. coli* W3110 pMBLe-*bla*_{NDM-1} and *E. coli* W3110 Δ *lacZ* pMBLe-*bla*_{NDM-4})
387 were grown at 37°C.

388 Cultures were then diluted 1/100 in fresh LB broth, and grown at 37°C to OD_{600nm} =
389 0.6. Equal amounts (according to OD_{600nm}) of Lac⁻ cells expressing one allele and
390 Lac⁺ cells producing the competing allele were mixed and diluted 1/500 in fresh LB
391 broth, supplemented with 20 µg/mL gentamycin, 100 µM IPTG, different
392 concentrations of cefotaxime, and either with or without addition of 250 µM DPA or
393 250 µg/mL CP. The greatest concentration of cefotaxime used was the maximum
394 allowing visible growth under each condition. The competition was then carried out

395 by growing the cells ON at 37°C, after which ca. 100-300 cells were plated in LB-
396 agar plates supplemented with 60 µg/mL X-Gal and 100 µM IPTG, and grown ON
397 at 37°C. Blue and white colonies were counted to determine the proportion of Lac⁺
398 and Lac⁻ cells, and thus of each variant, in the population after the competition. In
399 order to ensure there was no effect on fitness due to the Lac^{+/-} background, the
400 experiments were repeated inverting the strains carrying each allele.

401

402 **Determination of Zn(II) affinity in spheroplasts**

403 Spheroplasts from *E. coli* cells expressing NDM variants were centrifuged and
404 resuspended in Chelex-100-treated HEPES 10 mM, NaCl 200mM, pH 7.5.

405 Spheroplasts were diluted 1/50 in Chelex-100-treated HEPES 10 mM, NaCl
406 200mM, pH 7.5 with variable amounts of DPA (0-50 µM). After incubation at 30°C
407 for 10 min, 550 µM imipenem was added and β-Lactamase activity measured in a
408 JASCO V-670 spectrophotometer at 30°C. Imipenem hydrolysis was monitored at
409 300 nm ($\Delta\epsilon_{300\text{nm}} = -9,000 \text{ M}^{-1}\text{cm}^{-1}$).

410

411 **ACKNOWLEDGEMENTS**

412 G.B. is recipient of a doctoral fellowship from Consejo Nacional de Investigaciones
413 Científicas y Técnicas (CONICET). A.J.V. and L.J.G. are Staff members from
414 CONICET. This work was also supported by funds from: National Institute of
415 Allergy and Infectious Diseases of the National Institutes of Health under award
416 number R01AI100560. to A.J.V. and R.A.B. and Agencia Nacional de Promoción
417 Científica y Tecnológica (ANPCyT) to A.J.V. The Cleveland Department of

418 Veterans Affairs, the Veterans Affairs Merit Review Program award number
419 1I01BX001974, and the Geriatric Research Education and Clinical Center VISN 10
420 also support RAB. We thank Professor Elizabeth Nolan (MIT) for providing
421 calprotectin. The content is solely the responsibility of the authors and does not
422 necessarily represent the official views of the National Institutes of Health or the
423 Department of Veterans Affairs.

424

425 REFERENCES

- 426 1. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of
427 carbapenemases. *Front Microbiol* 4:48.
- 428 2. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in
429 Enterobacteriaceae: here is the storm! *Trends Mol Med* 18:263-72.
- 430 3. Prevention CfDCa. 2013. Antibiotic Resistance Threats in the United States
431 2013. Centers for Disease Control and Prevention, Atlanta, GA.
- 432 4. Palzkill T. 2013. Metallo-beta-lactamase structure and function. *Ann N Y*
433 *Acad Sci* 1277:91-104.
- 434 5. Crowder MW, Spencer J, Vila AJ. 2006. Metallo-beta-lactamases: novel
435 weaponry for antibiotic resistance in bacteria. *Acc Chem Res* 39:721-8.
- 436 6. Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of
437 NDM-1 positive bacteria in the New Delhi environment and its implications for
438 human health: an environmental point prevalence study. *Lancet Infect Dis* 11:355-
439 62.

- 440 7. Dortet L, Poirel L, Nordmann P. 2014. Worldwide Dissemination of the
441 NDM-Type Carbapenemases in Gram-Negative Bacteria. *Biomed Res Int*
442 2014:249856.
- 443 8. King D, Strynadka N. 2011. Crystal structure of New Delhi metallo-beta-
444 lactamase reveals molecular basis for antibiotic resistance. *Protein Sci* 20:1484-91.
- 445 9. Gonzalez LJ, Bahr G, Nakashige TG, Nolan EM, Bonomo RA, Vila AJ. 2016.
446 Membrane anchoring stabilizes and favors secretion of New Delhi metallo-beta-
447 lactamase. *Nat Chem Biol* 12:516-22.
- 448 10. Gonzalez LJ, Bahr G, Vila AJ. 2016. Lipidated beta-lactamases: from bench
449 to bedside. *Future Microbiol* 11:1495-1498.
- 450 11. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan
451 R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan
452 S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U,
453 Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S,
454 Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new
455 antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular,
456 biological, and epidemiological study. *Lancet Infect Dis* 10:597-602.
- 457 12. Khan AU, Maryam L, Zarrilli R. 2017. Structure, Genetics and Worldwide
458 Spread of New Delhi Metallo-beta-lactamase (NDM): a threat to public health. *BMC*
459 *Microbiol* 17:101.
- 460 13. Makena A, Brem J, Pfeffer I, Geffen RE, Wilkins SE, Tarhonskaya H,
461 Flashman E, Phee LM, Wareham DW, Schofield CJ. 2015. Biochemical
462 characterization of New Delhi metallo-beta-lactamase variants reveals differences
463 in protein stability. *J Antimicrob Chemother* 70:463-9.

- 464 14. Meini MR, Tomatis PE, Weinreich DM, Vila AJ. 2015. Quantitative
465 Description of a Protein Fitness Landscape Based on Molecular Features. *Mol Biol*
466 *Evol* 32:1774-87.
- 467 15. Gonzalez LJ, Moreno DM, Bonomo RA, Vila AJ. 2014. Host-specific
468 enzyme-substrate interactions in SPM-1 metallo-beta-lactamase are modulated by
469 second sphere residues. *PLoS Pathog* 10:e1003817.
- 470 16. Pasteran F, Gonzalez LJ, Albornoz E, Bahr G, Vila AJ, Corso A. 2016.
471 Triton Hodge Test: Improved Protocol for Modified Hodge Test for Enhanced
472 Detection of NDM and Other Carbapenemase Producers. *J Clin Microbiol* 54:640-
473 9.
- 474 17. Mira PM, Meza JC, Nandipati A, Barlow M. 2015. Adaptive Landscapes of
475 Resistance Genes Change as Antibiotic Concentrations Change. *Mol Biol Evol*
476 32:2707-15.
- 477 18. Brophy MB, Hayden JA, Nolan EM. 2012. Calcium ion gradients modulate
478 the zinc affinity and antibacterial activity of human calprotectin. *J Am Chem Soc*
479 134:18089-100.
- 480 19. Cerasi M, Ammendola S, Battistoni A. 2013. Competition for zinc binding in
481 the host-pathogen interaction. *Front Cell Infect Microbiol* 3:108.
- 482 20. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ,
483 Anderson KL, Dattilo BM, Dunman PM, Gerads R, Caprioli RM, Nacken W, Chazin
484 WJ, Skaar EP. 2008. Metal chelation and inhibition of bacterial growth in tissue
485 abscesses. *Science* 319:962-5.
- 486 21. Capdevila DA, Wang J, Giedroc DP. 2016. Bacterial Strategies to Maintain
487 Zinc Metallostasis at the Host-Pathogen Interface. *J Biol Chem* 291:20858-20868.

- 488 22. Gonzalez JM, Meini MR, Tomatis PE, Medrano Martin FJ, Cricco JA, Vila
489 AJ. 2012. Metallo-beta-lactamases withstand low Zn(II) conditions by tuning metal-
490 ligand interactions. *Nat Chem Biol* 8:698-700.
- 491 23. Knies JL, Cai F, Weinreich DM. 2017. Enzyme Efficiency but Not
492 Thermostability Drives Cefotaxime Resistance Evolution in TEM-1 beta-
493 Lactamase. *Mol Biol Evol* 34:1040-1054.
- 494 24. Suvorov M, Vakulenko SB, Mobashery S. 2007. Cytoplasmic-membrane
495 anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic
496 resistance. *Antimicrob Agents Chemother* 51:2937-42.
- 497 25. King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC,
498 Walsh TR, Coombes BK, Wright GD. 2014. Aspergillomarasmine A overcomes
499 metallo-beta-lactamase antibiotic resistance. *Nature* 510:503-6.
- 500 26. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25
501 years of image analysis. *Nat Methods* 9:671-5.
- 502 27. Institute CLS. 2012. Methods for Dilution Antimicrobial Susceptibility Tests
503 for Bacteria That Grow Aerobically; Approved Standard - Ninth Edition. CLSI
504 Document M07-A9. Clinical Laboratory Standards Institute, Wayne, PA.
- 505 28. Bachmann BJ. 1972. Pedigrees of some mutant strains of *Escherichia coli*
506 K-12. *Bacteriol Rev* 36:525-57.
- 507 29. Humbert MV, Rasia RM, Checa SK, Soncini FC. 2013. Protein signatures
508 that promote operator selectivity among paralog MerR monovalent metal ion
509 regulators. *J Biol Chem* 288:20510-9.

510

511

512

513 **FIGURE LEGENDS**

514 **Figure 1. NDM alleles possess a limited number of substitutions located**
515 **outside the active site. A**, NDM variants and their corresponding mutations with
516 respect to NDM-1. Substitutions occurring in two or more alleles are indicated in
517 bold. **B**, Diagram showing the cellular localization of NDM-1 within the inner leaflet
518 of the outer membrane in Gram-negative bacteria and crystal structure of NDM-1
519 (PDB: 4EYL), displaying the residues mutated in clinical alleles (spheres). Spheres
520 are colored with a gradient from white to black according to increasing frequency of
521 mutation at that position among alleles. Active site Zn(II) ions are indicated as
522 green spheres, and residues acting as metal ligands are displayed as sticks.

523

524 **Figure 2. NDM alleles display an increased tolerance to Zn(II) starvation with**
525 **respect to NDM-1.** Cefotaxime MICs for *E. coli* DH5 α cells expressing different
526 NDM alleles in growth medium supplemented with the indicated concentrations of
527 DPA, relative to the MIC in 0 μ M of DPA. Data corresponds to three independent
528 experiments, and is presented as mean \pm s.e.m.

529

530 **Figure 3. Clinical NDM variants possess enhanced *in vivo* stability upon**
531 **Zn(II) starvation. A**, MBL protein levels for NDM alleles in whole *E. coli* cells
532 quantified from western blots (Figure S3) as a function of time after addition of 500
533 μ M DPA, normalized to control samples not treated with DPA. Data are presented
534 as percentage of initial protein remaining after treatment with DPA, and correspond

535 to mean \pm s.e.m. of three independent experiments. Data points for each allele
536 were fitted to a first-order exponential decay, indicated as continuous curves. **B**,
537 Half-lives for NDM alleles, obtained from exponential decay fit of data in panel **A**.

538

539 **Figure 4. Substitution M154L leads to an increased Zn(II) binding affinity.**


540 Relative β -lactamase activity of spheroplasts from *E.coli* cells expressing NDM
541 alleles, after incubation for 10 min at 30°C with different concentrations of DPA.
542 Values are presented as relative to activity at 0 μ M DPA. Data corresponds to
543 three independent experiments, and is plotted as mean \pm s.e.m.


544


545 **Figure 5. NDM alleles outcompete NDM-1 under Zn(II) limiting conditions.**

546 Competition experiments between *E. coli* W3110 cells expressing NDM alleles in
547 presence of increasing concentrations of cefotaxime, in growth media with and
548 without supplementation with metal chelators. **A)** NDM-1 vs NDM-4. **B)** NDM-1 vs
549 NDM-6. **C)** NDM-4 vs NDM-15. **D)** NDM-1 vs NDM-15. Data are presented as
550 mean \pm s.e.m. of two independent determinations inverting the Lac+/Lac-
551 background of the strain carrying each allele.

552







B

Allele	$t_{1/2}$ (min)
NDM-1	9
NDM-2	8
NDM-3	13
NDM-4	11
NDM-5	20
NDM-6	61
NDM-7	18
NDM-8	11
NDM-9	53
NDM-10	<2
NDM-11	8
NDM-12	17
NDM-13	18
NDM-14	8
NDM-15	75
NDM-16	9

